Corbus Pharmaceuticals Holdings, Inc. Accrued Liabilities, Current
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had Accrued Liabilities, Current of $15.23 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $15.23M.
- 2026-03-31: Accrued Liabilities, Current $16.50M.
- 2025-12-31: Accrued Liabilities, Current $16.84M.
- 2025-09-30: Accrued Liabilities, Current $12.58M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $15.23M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $16.50M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $16.84M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $12.58M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $7.65M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $5.90M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $5.43M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $7.18M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $10.49M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $9.40M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $11.03M 10-K · filed 2025-03-11 | $11.03M 10-K · filed 2024-03-12 |
| 2023-09-30 | $7.55M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $6.42M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $6.47M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $6.00M 10-K · filed 2024-03-12 | |
| 2022-09-30 | $4.83M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $4.72M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $5.50M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $10.09M 10-K · filed 2023-03-07 | |
| 2021-09-30 | $13.37M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $15.09M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $17.74M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $22.01M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $28.59M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $28.14M 10-Q/A · filed 2020-08-31 | |
| 2020-03-31 | $23.52M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $22.45M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $23.97M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $19.06M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $15.56M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $9.85M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $7.39M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $5.80M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $5.90M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $4.74M 10-K · filed 2019-03-12 | |
| 2017-09-30 | $2.56M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $2.71M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $2.87M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $3.26M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $2.34M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $1.92M 10-Q · filed 2016-08-12 | |
| 2016-03-31 | $1.30M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $562.28K 10-K · filed 2017-03-08 | |
| 2015-09-30 | $466.12K 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $390.04K 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $293.99K 10-Q · filed 2015-05-13 | |
| 2014-12-31 | $249.49K 10-K · filed 2016-03-28 | |
| 2014-09-30 | $55.78K 10-Q · filed 2014-11-13 | |
| 2013-12-31 | $63.49K 10-K · filed 2015-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |